Amgen Inc.
Substituted piperazines as KRAS G12C inhibitors
Last updated:
Abstract:
Provided herein are KRAS G12C inhibitors, such as ##STR00001## composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
Status:
Grant
Type:
Utility
Filling date:
11 Jun 2019
Issue date:
29 Mar 2022